New treatment targeting IL-17A for idiopathic pulmonary fibrosis
IL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF)
This study is exploring a new treatment for idiopathic pulmonary fibrosis (IPF) that aims to reduce inflammation in the lungs, which could help improve lung function and quality of life for people living with this condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Targetsite Therapeutics Corporation NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10761365 on NIH RePORTER |
What this research studies
This research investigates a novel therapeutic approach for idiopathic pulmonary fibrosis (IPF) by targeting the IL-17A mRNA with specific oligonucleotide agents. These agents are designed to block the production of inflammatory cytokines that contribute to the progression of IPF, a condition that severely impacts lung function and quality of life. The study will utilize a bleomycin-induced lung fibrosis model to assess the effectiveness of this treatment. Patients may benefit from a new, potentially more tolerable treatment option that addresses the underlying inflammation associated with IPF.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are experiencing progressive symptoms.
Not a fit: Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from idiopathic pulmonary fibrosis.
How similar studies have performed: While targeting inflammatory pathways in IPF is a novel approach, similar strategies have shown promise in other inflammatory diseases, indicating potential for success.
Where this research is happening
New Haven, United States
- Targetsite Therapeutics Corporation — New Haven, United States (Active)
Researchers
- Principal investigator: Ramgolam, Vinod Satisch — Targetsite Therapeutics Corporation
- Study coordinator: Ramgolam, Vinod Satisch
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.